| Literature DB >> 24900506 |
Fabio Del Bello1, Eleonora Diamanti1, Mario Giannella1, Valerio Mammoli1, Carla Marchioro2, Laura Mattioli3, Federica Titomanlio3, Alessandro Piergentili1, Wilma Quaglia1, Giovanni Benedetti4, Maurizio Varrone4, Maria Pigini1.
Abstract
This study demonstrated that cyclomethyline (2) and the corresponding enantiomers (R)-(-)-2 and (S)-(+)-2, displaying α2C-adrenoreceptor (AR) agonism/α2A-AR antagonism, similarly to allyphenyline (1) and its enantiomers, significantly decreased the naloxone-precipitated withdrawal symptoms in mice at very low doses. It also highlighted that such positive effects on morphine dependence can even be improved by additional serotoninergic 5-HT1A receptor (5-HT1A-R) activation. Indeed, 1 or the single (S)-(+)-1, 2, or both its enantiomers, all behaving as α2C-AR agonists/α2A-AR antagonists/5-HT1A-R agonists, alone and at the same low dose, improved morphine withdrawal syndrome and exerted a potent antidepressant-like effect. Therefore, considering the elevated comorbidity between opiate abuse and depressed mood and the benefit of these multifunctional compounds to both disorders, it is possible that they prove more efficacious and less toxic than a cocktail of drugs in managing opioid addiction.Entities:
Keywords: 5-HT1A-R agonists; antidepressant-like effect; morphine withdrawal symptoms reduction; α2-adrenergic ligands
Year: 2012 PMID: 24900506 PMCID: PMC4025786 DOI: 10.1021/ml300064v
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345